A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer

被引：0

作者：

Vergote, I. ^{[1
]}

Dean, E. ^{[2
]}

Lassen, U. ^{[3
]}

de Bono, J. ^{[4
]}

Drew, Y. ^{[5
]}

Machiels, J-P. ^{[6
]}

Nielsen, D. ^{[7
]}

Arkenau, H-T. ^{[8
]}

Forster, M. ^{[9
]}

Jones, R. ^{[10
]}

Slomovitz, B. ^{[11
]}

Spicer, J. ^{[12
]}

Johnson, M. ^{[13
]}

Cornez, N. ^{[14
]}

Gennigens, C. ^{[15
]}

Fulton, B. ^{[16
]}

Lisby, S. ^{[17
]}

Basse, L. ^{[18
]}

Coleman, R. ^{[19
]}

Hong, D. S. ^{[20
]}

机构：

[1] Univ Hosp Leuven, Gynaecol Verloskunde, Leuven, Belgium

[2] Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England

[3] Rigshosp, Dept Oncol, Phase Unit 1, Copenhagen, Denmark

[4] Royal Marsden Hosp, Inst Canc Res, Sect Med, Sutton, Surrey, England

[5] Newcastle Gen Hosp, Freeman Hosp, Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England

[6] Roi Albert II, Oncol, Brussels, Belgium

[7] Herlev & Gentofte Hosp, Dept Oncol, Herlev, Denmark

[8] Sarah Cannon Res Inst SCRI UK, Oncol, London, England

[9] UCL, Canc Inst, Oncol, London, England

[10] Velindre Hosp, Velindre Canc Ctr, Oncol, Cardiff, S Glam, Wales

[11] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[12] Kings Coll London, Guys Hosp, Oncol, London, England

[13] Sarah Cannon Res Inst, Oncol, Nashville, TN USA

[14] Ctr Hosp Univ & Psychiat Mons Borinage, Oncol, Mons, Belgium

[15] Ctr Hosp Uuniv Sart Tilman, Oncol, Liege, Belgium

[16] Beatson West Scotland Canc Ctr, Oncol, Glasgow, Lanark, Scotland

[17] Genmab AS, Med Dept, Copenhagen, Denmark

[18] Genmab, Med Dept, Copenhagen, Denmark

[19] MD Anderson Canc Ctr, Oncol, Houston, TX USA

[20] Univ Texas MD Anderson Canc Ctr, Phase Unit 1, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

931O

引用

页数：2

共 50 条

[21] A prospective study of gefitinib in patients with recurrent or metastatic cervical cancer
Krishna, A.
Ms, A.
Fernandes, D.
Ag, H.
Rao, S.
Shankar, S.
Banerjee, S.
Sunny, J.
Srinivas, C.
Lobo, D.
ANNALS OF ONCOLOGY, 2022, 33 : S386 - S386
[22] A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer
Friedman, C. F.
Snyder, A.
Sharon, E.
De Meritens, A. Buckley
Cantrell, L. A.
Corr, B. R.
Konner, J.
Konstantinopoulos, P. A.
Soldan, K.
Aghajanian, C. A.
Zamarin, D.
GYNECOLOGIC ONCOLOGY, 2019, 154 : 17 - 18
[23] Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).
Vergote, Ignace
Concin, Nicole
Mirza, Mansoor Raza
Andreassen, Camilla Mondrup
Lorusso, Domenica
Gennigens, Christine N.
Banerjee, Susana N.
O'Cearbhaill, Roisin Eilish
Campos, Susana
Nicacio, Leonardo Viana
Eaton, Lamar
O'Malley, David M.
Soumaoro, Ibrahima
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Coleman, Robert L.
Lorusso, Domenica
Gennigens, Christine
Gonzalez-Martin, Antonio
Randall, Leslie
Cibula, David
Lund, Bente
Woelber, Linn
Pignata, Sandro
Forget, Frederic
Redondo, Andres
Vindelov, Signe Diness
Chen, Menghui
Harris, Jeffrey R.
Smith, Margaret
Nicacio, Leonardo Viana
Teng, Melinda S. L.
Laenen, Annouschka
Rangwala, Reshma
Manso, Luis
Mirza, Mansoor
Monk, Bradley J.
Vergote, Ignace
LANCET ONCOLOGY, 2021, 22 (05): : 609 - 619
[25] Phase II study of weekly topotecan in recurrent or metastatic cervical cancer: a GEICO study
Rubio, M.
Santaballa, A.
Garcia, Y.
Gonzalez, A.
Bover, I.
Calvo, E.
Contreras, J. A.
del Campo, J.
De Juan, A.
Poveda, A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26] A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer
Xin, Lingli
Ye, Mei
Gao, Yuan
Xiong, Qi
Hou, Qingxiang
TRANSLATIONAL CANCER RESEARCH, 2024, 13 (07) : 3718 - 3728
[27] A multi-center phase II study of tirapazamine plus cisplatin in patients with metastatic or recurrent cervical cancer
Aghajanian, C
Levenbeck, C
Chen, Y
Pezzulli, S
Brown, C
Curtin, J
von Roemeling, R
Spriggs, D
ANNALS OF ONCOLOGY, 1998, 9 : 174 - 174
[28] Maintenance therapy for patients with recurrent or metastatic cervical cancer: A multicentre, cohort study
Peng, Chen
Guo, Qiufen
Zhang, Tingting
Chen, Jinlong
Liu, Naifu
Yan, Peile
Lu, Yuanyuan
Ma, Anqun
Lv, Pengzhong
Liu, Jing
Xie, Peng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer
Aghajanian, C
Brown, C
OFlaherty, C
Fleischauer, A
Curtin, J
vonRoemeling, R
Spriggs, DR
GYNECOLOGIC ONCOLOGY, 1997, 67 (02) : 127 - 130
[30] Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301
Manso, Luis
Vergote, Ignace
Fujiwara, Keiichi
Angelergues, Antoine
Zikan, Michal
Jordan, Scott
Lee, Jung-Yun
Barraclough, Lisa
Maluf, Fernando Cotait
Lorusso, Domenica
Yonemori, Kan
Gennigens, Christine
Martin, Antonio Gonzalez
Heitz, Florian
Westermann, Anneke M.
Covens, Allan
Whalley, Elizabeth
Chen, Yiyi
Soumaoro, Ibrahima
Randall, Leslie M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →